Gopinadh Bhyrapuneni
Road 5, Avenue 7, Banjara Hills
Hyderabad, TG 500034, India
Hyderabad, TG 500034, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
Journal: Clinical drug investigation
Published: March 11, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders.
Journal: Journal of psychopharmacology (Oxford, England)
Published: February 06, 2021
The use of inactivated brain homogenate to determine the in vitro fraction unbound in brain for unstable compounds.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 06, 2020
Evaluation of monoamine oxidase A and B type enzyme occupancy using non-radiolabelled tracers in rat brain.
Journal: Neurochemistry international
Published: June 03, 2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
Journal: Clinical drug investigation
Published: May 14, 2020
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
Journal: Psychopharmacology
Published: February 19, 2020
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.
Journal: Journal of medicinal chemistry
Published: February 07, 2020
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: January 31, 2020
Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: June 06, 2019
A definite measure of occupancy exposures, seeking with non-radiolabeled in vivo 5-HT2A receptor occupancy and in vitro free fractions.
Journal: Journal of receptor and signal transduction research
Published: November 28, 2018
Assessment of sigma-1 receptor occupancy in mice with non-radiolabelled FTC-146 as a tracer.
Journal: Journal of receptor and signal transduction research
Published: June 19, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization.
Journal: Behavioural pharmacology
Published: May 31, 2018
Last Updated: 09/26/2026